News Release Details

Recent publications in the prominent Journal of Neurosurgery and Stroke provide new evidence supporting the clinical value of the Swoop system in stroke care and neurosurgical settings.

GUILFORD, Conn.--(BUSINESS WIRE)--Jul. 30, 2026-- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced the release of multiple peer-reviewed publications in the Journal of Neurosurgery and in Stroke, building evidence to support the value of the low field portable MRI in the neurosurgical and stroke treatment sites of care.

The July 2026 issue of the Journal of Neurosurgery featured cases performed in an ambulatory neurosurgery center in which the Swoop system provided access to imaging immediately following endovascular neurosurgical procedures, confirming the absence of findings such as acute ischemic or intracranial hemorrhage and thus enabling same-day discharge. Rapid evaluation of the cause of post-procedural neurological deficits is critical, and post-operative neuroimaging plays a central role in detecting complications and guiding clinical decision-making. Conventional MRI is often impractical or untimely, making the Swoop system uniquely positioned to bring value in the neurosurgical setting.

In addition, Stroke, one of the premier journals in cerebrovascular disease, recently published a collection of articles highlighting the value of low-field MRI across the stroke continuum, including pre-hospital stroke care, acute stroke, neurocritical care, and cerebral small vessel disease. Collectively, the articles review the existing body of data, provide new evidence, and highlight the role of low-field MRI in stroke care with practical guidance for successful implementation. This dedicated collection of publications illustrates the strong position that the Swoop system has established in stroke care and highlights its growing adoption as an emerging approach to stroke imaging, bringing value beyond the critical care environment and into the emergency department and stroke centers.

“These publications are important because they demonstrate the mounting clinical evidence supporting use of the Swoop system beyond the initial use in critical care, across many care settings,” said Edmond Knopp, MD, Hyperfine Chief Medical Officer. “The cases published in the Journal of Neurosurgery provide early evidence that immediate access to on-site imaging can inform post-procedural decision-making and help avoid unnecessary delays or hospital admissions. In addition, the broad body of published peer-reviewed and real-world evidence in stroke care marks an important milestone in the evolution of portable, ultra-low-field MRI, strengthening clinical confidence and supporting its transition from an early-stage technology to routine clinical use. Collectively, these publications strengthen the clinical foundation of the Swoop system and highlight its potential to enable more accessible, efficient, and cost-effective neuroimaging across multiple care settings.”

The use of the Swoop system in support of imaging for a broad range of clinical applications is supported by a robust body of evidence with more than 180 peer-reviewed publications and editorials and over 280 scientific presentations spanning multiple sites of care.

Patel D, Jaikumar V, Morioka TPT, et al. Implementation and clinical utility of ultra-low-field portable magnetic resonance imaging for postprocedural neurological evaluation in ambulatory neurosurgery: illustrative cases. Journal of Neurosurgery: Case Lessons. 2026;12(3): e CASE26245. doi:10.3171/CASE26245

Stroke publications: Stroke Online Journal

For more information about the Swoop® system, please visit HyperfineMRI.com.

About the Swoop® Portable MRI Systems

The Swoop® Portable MR Imaging® Systems are U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. They are portable, ultra-low-field magnetic resonance imaging devices for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis.

About Hyperfine, Inc.

Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit HyperfineMRI.com.

Hyperfine, the Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine. The Swoop logo, Optive AI logo, and Optive AI are trademarks of Hyperfine.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the “Company”) may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s goals and commercial plans, the benefits of the Company’s products and services, and the Company’s future performance and its ability to implement its strategy, including its entrance into new markets. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company’s product development and commercialization activities, including the degree that the Swoop® system is accepted and used by healthcare professionals; the Company’s inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to progress on product advancements and improvements; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services and reimbursement for medical procedures conducted using the Company’s products and services; existing and potential future National Institutes of Health funding pressures; existing and potential future effects from U.S. export controls and tariffs; the Company’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties indicated from time to time in the Company’s filings with the Securities and Exchange Commission, including those under “Risk Factors” therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260730383399/en/

Media Contact
Devin Zell
Hyperfine
dzell@hyperfine.io

Investor Contact
Webb Campbell
Gilmartin Group LLC
webb@gilmartinir.com

Source: Hyperfine, Inc.